Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,399,496

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,399,496 protect, and when does it expire?

Patent 8,399,496 protects CAYSTON and is included in one NDA.

This patent has fifty-six patent family members in twenty-one countries.

Summary for Patent: 8,399,496
Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA), Keller; Manfred (Munchen, DE), Lintz; Frank-Christophe (Starnberg, DE)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/229,425
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 8,399,496

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,399,496

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053305 ⤷  Sign up for a Free Trial
Austria 502623 ⤷  Sign up for a Free Trial
Australia 2002231244 ⤷  Sign up for a Free Trial
Australia 2004257632 ⤷  Sign up for a Free Trial
Australia 2009233632 ⤷  Sign up for a Free Trial
Australia 2012202089 ⤷  Sign up for a Free Trial
Australia 2014271333 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.